多嚢胞性卵巣症候群治療の世界市場：2025年～2033年

世界の多嚢胞性卵巣症候群治療市場は、2024年に36億6,000万米ドルに達し、2033年までには63億9,000万米ドルに達すると予測され、予測期間中の2025年から2033年のCAGRは6.8%で成長する見込みです。

多嚢胞性卵巣症候群（PCOS）は、生殖年齢にある個人に影響を及ぼす一般的なホルモン疾患で、生殖ホルモン、特にアンドロゲンの不均衡が特徴です。この疾患は、不規則な月経周期、生理不順、予測不可能な排卵など、様々な症状によって現れます。PCOSは嚢胞の存在を示唆する病名ですが、すべてのPCOS患者が卵巣嚢腫を持つわけではありません。

PCOSでは、卵巣が高レベルのアンドロゲンを産生します。アンドロゲンは一般的に男性ホルモンですが、女性にも低レベルで存在します。この過剰は正常な月経周期を乱し、生理不順や無排卵を引き起こします。PCOS患者の多くは、排卵の障害により、月経の頻度が低かったり、長引いたりします。アンドロゲン濃度が高いと、多毛症、にきび、薄毛になることがあります。診断に必要なものではありませんが、卵子がうまく発育しないために、超音波検査で小さな液体が入った袋が見られることがあります。

PCOSは、女性および出生時に女性と割り当てられた人（AFAB）の不妊の主な原因の1つです。PCOSに伴うホルモンバランスの乱れは排卵を妨げ、妊娠を難しくします。妊娠を望むPCOS患者には、生活習慣の改善、排卵を誘発する薬物療法、体外受精（IVF）などの生殖補助医療などの治療法があります。これらの要因が、世界の多嚢胞性卵巣症候群治療市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

PCOSの有病率の増加

PCOSの有病率の増加が世界の多嚢胞性卵巣症候群治療市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予測されています。PCOSは無排卵の主な原因であり、女性の不妊の主な原因となっています。この症候群に伴うホルモンバランスの乱れは、正常な排卵プロセスを乱し、罹患者の妊娠を困難にしています。PCOSのこのような側面は、身体的な健康に影響を与えるだけでなく、不妊症にしばしば関連するストレスや失望感により、感情的・心理的な影響ももたらします。

2023年6月のWHO（世界保健機関）のデータによると、多嚢胞性卵巣症候群（PCOS）は、世界中の生殖年齢にある女性の推定8％から13％が罹患する重大な健康問題です。この疾患は、月経不順や不妊症など様々な症状を引き起こすホルモンバランスの乱れを特徴とします。憂慮すべきことに、PCOSを持つ女性の最大70％が診断されておらず、このことは認識とヘルスケアへのアクセスにおける重大なギャップを浮き彫りにしています。

PCOSは複雑な疾患であり、タイムリーな診断と管理のためには、認知度の向上が必要です。この症候群に罹患した人々の転帰を改善するためには、理解と医療アクセスのギャップに対処することが極めて重要です。これらすべての要因が、世界の多嚢胞性卵巣症候群治療市場に需要をもたらしています。

さらに、業界の主要企業は、世界の多嚢胞性卵巣症候群治療市場の成長を促進する革新的なソリューションと投資に、より焦点を当てています。例えば、2024年12月、Gytreeは多嚢胞性卵巣症候群（PCOS）の管理に役立つよう特別に処方されたインド初のプロテインを発表し、女性のホルモンの健康に対する革新的なソリューションを提供しました。この革新的なプロテインサプリメントには、PCOS症状の緩和効果が認められている主要成分であるイノシトールが豊富に配合されています。さらに、16種類以上のスーパーフードと必須栄養素を配合し、ホルモンバランスと健康全般を促進するよう設計されています。

また、2024年5月には、多嚢胞性卵巣症候群（PCOS）患者のニーズに対応することに焦点を当てた臨床段階の医療機器企業であるMay Healthが、2,500万米ドルのシリーズB資金調達ラウンドを完了しました。この資金調達ラウンドは、BpifranceとTrill Impactが共同で主導し、創業投資家のSofinnova Partners、Avestria Ventures、Kidron Capital Assets LPが貢献しました。さらに、ライフスタイル管理に対する需要の高まりが、世界の多嚢胞性卵巣症候群治療市場の拡大に寄与しています。

承認された治療薬の欠如

多嚢胞性卵巣症候群（PCOS）に特化した治療薬が承認されていないことは、この複雑なホルモン障害を管理する上で大きな課題となっています。PCOSに関連する症状を緩和するために様々な薬剤が利用されていますが、米国食品医薬品局（FDA）のような規制機関から、この症状に対してのみ正式に承認された薬剤はありません。

PCOSの治療の多くは、既存の薬剤の適応外使用です。例えば、エストロゲンとプロゲスチンを含む経口避妊薬（COC）は、月経周期を調節し、多毛やニキビなどの症状を管理するために頻繁に処方されます。しかし、これらの薬剤はPCOSに対して特別に承認されているわけではなく、本症そのものを対象とした治療として認識されているというよりは、症状を緩和する効果に基づいて使用されています。

メトホルミンやクエン酸クロミフェンなどの他の薬剤は、それぞれインスリン抵抗性の管理や排卵誘発のために処方されることが多いです。これらの薬剤はPCOSのある側面に対しては有効性を示していますが、本症のホルモンバランスの乱れに包括的に対処しているわけではありません。例えば、メトホルミンは主にインスリン感作作用のために利用されていますが、PCOSに特徴的なホルモン異常に対する専用の治療薬ではありません。したがって、上記の要因が世界の多嚢胞性卵巣症候群治療市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • PCOSの罹患率の増加
  • 抑制要因
    • 承認された治療薬の不足
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 薬剤クラス別

• 経口避妊薬
  • エチニルエストラジオール+プロゲスチン
  • レボノルゲストレル
  • ドロスピレノン
  • デソゲストレル
  • ノルゲスティメート
  • シプロテロン酢酸塩
  • プロゲスチン
• インスリン抵抗性改善薬
  • メトホルミン
  • チアゾリジンジオン（TZD）
• 抗アンドロゲン
  • スピロノラクトン
  • フィナステリド
• 抗肥満薬
  • オルリスタット
  • リラグルチド
• その他
• 外科手術
  • 卵巣楔状切除術
  • 腹腔鏡下卵巣穿孔術

第7章 エンドユーザー別

• 病院
• 専門クリニック
• その他

第8章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第9章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第10章 企業プロファイル

• Teva Pharmaceuticals USA, Inc.
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 過去および予測の製品販売
    • 製品販売量
  • 財務概要
    • 会社の収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Bayer AG
• Johnson & Johnson
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• GSK plc.
• Pfizer Inc.
• CMP Pharma
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• CHEPLAPHARM Arzneimittel GmbH（H2 Pharma）

第11章 付録

The global polycystic ovarian syndrome treatment market reached US$ 3.66 billion in 2024 and is expected to reach US$ 6.39 billion by 2033, growing at a CAGR of 6.8 % during the forecast period 2025-2033.

Polycystic ovary syndrome (PCOS) is a common hormonal disorder that affects individuals of reproductive age, marked by an imbalance in reproductive hormones, especially androgens. This condition can manifest through various symptoms, including irregular menstrual cycles, missed periods, and unpredictable ovulation. Despite its name suggesting the presence of cysts, not all individuals with PCOS have ovarian cysts; they can still experience hormonal imbalances and related symptoms.

In PCOS, the ovaries produce elevated levels of androgens, which are typically male hormones but also exist in lower levels in females. This excess can disrupt the normal menstrual cycle, leading to irregular or absent periods and anovulation. Many individuals with PCOS have infrequent or prolonged menstrual periods due to disrupted ovulation. High androgen levels can result in hirsutism, acne, and hair thinning. Although not necessary for diagnosis, small fluid-filled sacs may be seen on ultrasounds as a result of immature eggs that do not develop properly.

PCOS is one of the leading causes of infertility among women and those assigned female at birth (AFAB). The hormonal imbalances associated with PCOS can impede ovulation, making conception difficult. For individuals with PCOS who wish to become pregnant, treatment options may include lifestyle changes, medications to induce ovulation, or assisted reproductive technologies such as in vitro fertilization (IVF). These factors have driven the global polycystic ovarian syndrome treatment market expansion.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of PCOS

The increasing prevalence of PCOS is significantly driving the growth of the global polycystic ovarian syndrome treatment market and is expected to drive throughout the market forecast period. PCOS is the leading cause of anovulation, which is a primary contributor to infertility among women. The hormonal imbalances associated with this syndrome can disrupt the normal ovulation process, making it challenging for affected individuals to conceive. This aspect of PCOS not only impacts physical health but also carries emotional and psychological consequences due to the stress and disappointment often linked with infertility.

According to the WHO (World Health Organization) data in June 2023, polycystic ovary syndrome (PCOS) is a significant health issue that affects an estimated 8-13% of women of reproductive age worldwide. This condition is characterized by hormonal imbalances that can lead to various symptoms, such as irregular menstrual cycles and infertility. Alarmingly, up to 70% of women with PCOS remain undiagnosed, which underscores a critical gap in awareness and access to healthcare.

PCOS is a complex condition that requires increased awareness for timely diagnosis and management. Addressing the gaps in understanding and healthcare access is crucial for improving outcomes for those affected by this syndrome. All these factors demand the global polycystic ovarian syndrome treatment market.

Furthermore, key players in the industry more focus on the innovative solutions and investments that would propel this market growth in the global polycystic ovarian syndrome treatment market. For instance, in December 2024, Gytree introduced India's first protein specifically formulated to help manage polycystic ovary syndrome (PCOS), providing an innovative solution for women's hormonal health. This innovative protein supplement is enriched with inositol, a key ingredient recognized for its effectiveness in alleviating PCOS symptoms. Additionally, the product features over 16 superfoods and essential nutrients designed to promote hormonal balance and overall well-being.

Also, in May 2024, May Health, a clinical-stage medical device company focused on addressing the needs of individuals with polycystic ovary syndrome (PCOS), completed a $25 million Series B financing round. This funding round was co-led by Bpifrance and Trill Impact, with contributions from founding investor Sofinnova Partners, as well as Avestria Ventures and Kidron Capital Assets LP. Moreover, the rising demand for lifestyle management contributes to the global polycystic ovarian syndrome treatment market expansion.

Lack of Approved Therapeutics

The absence of approved therapeutics specifically designed for polycystic ovary syndrome (PCOS) presents a significant challenge in managing this complex hormonal disorder. While various medications are utilized to alleviate symptoms associated with PCOS, none have received official approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) solely for this condition.

Many treatments for PCOS involve off-label use of existing medications. For example, combined oral contraceptives (COCs), which contain estrogen and progestin, are frequently prescribed to regulate menstrual cycles and manage symptoms like hirsutism and acne. However, these medications are not specifically approved for PCOS; they are used based on their effectiveness in alleviating symptoms rather than being recognized as targeted treatments for the syndrome itself.

Other medications, such as metformin and clomiphene citrate, are often prescribed to manage insulin resistance and induce ovulation, respectively. While these drugs have shown efficacy in treating certain aspects of PCOS, they do not comprehensively address the syndrome's hormonal imbalances. For instance, metformin is primarily utilized for its insulin-sensitizing effects but is not a dedicated treatment for the hormonal disturbances characteristic of PCOS. Thus, the above factors could be limiting the global polycystic ovarian syndrome treatment market's potential growth.

Segment Analysis

The global polycystic ovarian syndrome treatment market is segmented based on drug class, end-user, and region.

Drug Class:

The oral contraceptives segment is expected to dominate the global polycystic ovarian syndrome treatment market share

The oral contraceptives segment holds a major portion of the global polycystic ovarian syndrome treatment market share and is expected to continue to hold a significant portion of the global polycystic ovarian syndrome treatment market share during the forecast period.

Oral contraceptives, commonly referred to as birth control pills or "the pill," are the primary long-term treatment option for individuals with intact ovaries who have Polycystic Ovary Syndrome (PCOS) and do not wish to become pregnant. These contraceptives contain the hormones estrogen and progestin, which play a crucial role in managing PCOS symptoms. Oral contraceptives used in the PCOS are levonorgestrel, drospirenone, desogestrel, norgestimate, cyproterone acetate, and progestin variants.

In the treatment of polycystic ovary syndrome (PCOS), oral contraceptives (OCs) play a crucial role, primarily by regulating menstruation. These medications also help reduce symptoms such as hirsutism and acne by lowering testosterone levels. The most commonly prescribed OCs for addressing these androgenic symptoms are combinations of estrogen and progestogen. These newer formulations are considered more effective than earlier versions in managing these symptoms.

As per the National Center for Biotechnology Information (NCBI) research study in August 2022, after approximately six months of OC therapy, many women with hirsutism report noticeable clinical improvement. Research indicates that combining OCs with anti-androgens may create a synergistic effect, enhancing treatment outcomes. It is essential to provide treatment for PCOS not only to alleviate symptoms but also to prevent long-term complications associated with the disorder.

The primary mechanism of action for oral contraceptives in treating PCOS is their ability to regulate menstruation. Additionally, these medications help reduce symptoms such as hirsutism and acne by lowering testosterone levels. As a result, oral contraceptives are considered a primary treatment option for managing PCOS. These factors have solidified the segment's position in the global polycystic ovarian syndrome treatment market.

Geographical Analysis

North America is expected to hold a significant position in the global polycystic ovarian syndrome treatment market share

North America holds a substantial position in the global polycystic ovarian syndrome treatment market and is expected to hold most of the market share. The increasing incidence of PCOS among women in North America serves as a primary driver for market expansion. Research indicates that approximately 5 to 6 million women in the U.S. are affected by this condition, with a notable rise in diagnoses due to enhanced awareness and improved access to healthcare services.

The high rates of obesity and overweight individuals in North America significantly contribute to the growing number of PCOS cases. Obesity is a major risk factor for developing PCOS, and as obesity rates continue to rise, so does the incidence of this syndrome. Ongoing research and development efforts are leading to new therapeutic alternatives for PCOS. Innovations such as controlled ovarian stimulation (COS) therapies are being explored, which may enhance the effectiveness and variety of available treatments.

Furthermore, a major number of key player's presence, well-advanced healthcare infrastructure, government initiatives, and awareness programs would propel this global polycystic ovarian syndrome treatment market growth in the region. For instance, in September 2023, Ulike, a leading at-home IPL hair removal brand, is actively supporting individuals affected by polycystic ovary syndrome (PCOS) through its We See You campaign, launched in honor of PCOS Awareness Month in September. This initiative aims to raise awareness about PCOS and provide supportive solutions for hirsutism, a common symptom of the condition characterized by excessive hair growth.

Also, in August 2023, Celmatix, partnered with Ache Laboratorios, a prominent Brazilian pharmaceutical firm, to explore a novel melatonin receptor agonist aimed at treating polycystic ovary syndrome (PCOS). This collaboration is particularly noteworthy as it investigates a new mechanism of melatonin receptor action outside the central nervous system (CNS), which could lead to effective treatment options for women experiencing PCOS. Thus, the above factors are consolidating the region's position as a dominant force in the global polycystic ovarian syndrome treatment market.

Asia Pacific is growing at the fastest pace in the global polycystic ovarian syndrome treatment market share

Asia Pacific holds the fastest pace in the global polycystic ovarian syndrome treatment market and is expected to hold most of the market share. The increasing incidence of PCOS among women in the APAC region is a major driver of market growth. Studies indicate that the prevalence of PCOS varies widely across countries, with estimates ranging from 2% to 26%. This growing recognition of the syndrome is leading to more diagnoses and subsequent demand for effective treatment options.

As per Ministry of Science & Technology data in January 2023, the global prevalence of polycystic ovary syndrome (PCOS) varies significantly, with estimates ranging from 6% to 26%. In India, the reported prevalence falls between 3.7% and 22.5%. These discrepancies can be attributed to differences in diagnostic criteria, demographic factors, and environmental influences. According to the World Health Organization (WHO), PCOS affects approximately 8-13% of women of reproductive age worldwide. This range is consistent with findings from various studies that emphasize the widespread nature of this condition.

Improvements in healthcare infrastructure across APAC countries are facilitating better access to diagnostic and therapeutic services for PCOS. Enhanced facilities and trained healthcare professionals are essential for effectively managing this complex condition. Various government programs and health organizations are focusing on women's health issues, including PCOS. Initiatives aimed at increasing awareness, improving diagnosis, and providing support for treatment options are contributing to market growth.

Furthermore, key players in the region have innovative launches that would drive the global polycystic ovarian syndrome treatment market growth. For instance, in August 2024, in India, Aurelle Health launched as India's first direct-to-consumer (D2C) nutraceutical brand dedicated to women's hormonal health. This initiative is driven by the concerning statistic that 1 in 5 Indian women suffers from hormonal issues, such as polycystic ovary syndrome (PCOS). Thus, the above factors are consolidating the region's position as the fastest-growing force in the global polycystic ovarian syndrome treatment market.

Competitive Landscape

The major global players in the polycystic ovarian syndrome treatment market include Teva Pharmaceuticals USA, Inc., Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, GSK plc., Pfizer Inc., CMP Pharma, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, and CHEPLAPHARM Arzneimittel GmbH (H2 Pharma) among others.

Key Developments

• In November 2024, CORONA Remedies is preparing to launch a new manufacturing facility in Bhayla, Ahmedabad, aimed at producing essential female hormone products. This state-of-the-art plant will focus on creating treatments for various health conditions, including dysmenorrhea, polycystic ovary syndrome (PCOS), infertility, premenstrual syndrome (PMS), and other hormonal disorders.
• In October 2024, Wisp, the largest dedicated women's telehealth company in the U.S., announced a significant expansion of its services with the launch of a weight care vertical. This initiative aims to provide personalized online healthcare consultations for women, specifically targeting hormonal imbalances associated with conditions such as perimenopause, menopause, polycystic ovary syndrome (PCOS), and endometriosis.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-world Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global polycystic ovarian syndrome treatment market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by End-User
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of PCOS
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of Approved Therapeutics
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Drug Class

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 6.1.2. Market Attractiveness Index, By Drug Class
• 6.2. Oral Contraceptives*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Ethinyl Estradiol + Progestins
  • 6.2.4. Levonorgestrel
  • 6.2.5. Drospirenone
  • 6.2.6. Desogestrel
  • 6.2.7. Norgestimate
  • 6.2.8. Cyproterone Acetate
  • 6.2.9. Progestin
• 6.3. Insulin-Sensitizing Agents
  • 6.3.1. Metformin
  • 6.3.2. Thiazolidinediones (TZDs)
• 6.4. Antiandrogens
  • 6.4.1. Spironolactone
  • 6.4.2. Finasteride
• 6.5. Anti-Obesity Drugs
  • 6.5.1. Orlistat
  • 6.5.2. Liraglutide
• 6.6. Others
• 6.7. Surgical Procedures
  • 6.7.1. Ovarian Wedge Resection
  • 6.7.2. Laparoscopic Ovarian Drilling

7. By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Specialty Clinics
• 7.4. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Spain
    • 8.3.5.5. Italy
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. South Korea
    • 8.5.5.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

• 10.1. Teva Pharmaceuticals USA, Inc.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
    • 10.1.2.1. Product Description
    • 10.1.2.2. Product Key Performance Indicators (KPIs)
    • 10.1.2.3. Historic and Forecasted Product Sales
    • 10.1.2.4. Product Sales Volume
  • 10.1.3. Financial Overview
    • 10.1.3.1. Company Revenue's
    • 10.1.3.2. Geographical Revenue Shares
    • 10.1.3.3. Revenue Forecasts
  • 10.1.4. Key Developments
    • 10.1.4.1. Mergers & Acquisitions
    • 10.1.4.2. Key Product Development Activities
    • 10.1.4.3. Regulatory Approvals etc.
  • 10.1.5. SWOT Analysis
• 10.2. Bayer AG
• 10.3. Johnson & Johnson
• 10.4. Bristol-Myers Squibb Company
• 10.5. Takeda Pharmaceutical Company Limited
• 10.6. GSK plc.
• 10.7. Pfizer Inc.
• 10.8. CMP Pharma
• 10.9. Merck & Co., Inc.
• 10.10. F. Hoffmann-La Roche Ltd
• 10.11. CHEPLAPHARM Arzneimittel GmbH (H2 Pharma)

LIST NOT EXHAUSTIVE

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us